Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

Pers / media: Expert Comment › Popular

Periode	29-apr.-2022

Media-aandacht

Titel	Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Media naam/outlet	The Lancet
Mediatype	Other
Release datum	29/04/2022
URL	https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00093-5/fulltext
Personen	Dieuwke Broekstra